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Abstract
Awareness of the importance of maintaining physical health for patients with severe mental illnesses has recently
been on the increase. Although there are several elements contributing to poor physical health among these
patients as compared with the general population, risk factors for cardiovascular disease such as smoking, diabetes
mellitus, hypertension, dyslipidemia, metabolic syndrome, and obesity are of particular significance due to their
relationship with mortality and morbidity. These patients present higher vulnerability to cardiovascular risk factors
based on several issues, such as genetic predisposition to certain pathologies, poor eating habits and sedentary
lifestyles, high proportions of smokers and drug abusers, less access to regular health care services, and potential
adverse events during pharmacological treatment. Nevertheless, there is ample scientific evidence supporting the
benefits of lifestyle interventions based on diet and exercise designed to minimize and reduce the negative impact
of these risk factors on the physical health of patients with severe mental illnesses.
Introduction
It is well known that patients with severe mental illnesses
(SMIs) such as schizophrenia, depression, or bipolar dis-
order have worse physical health and reduced life expec-
tancy compared to the general population [1-4]. There
are data suggesting that patients with SMIs die on aver-
age between 13.5 and 32.2 years earlier than the general
population. A recent study, using years of potential life
lost (YPLL) as a measure of premature mortality showed
that the mean YPLL in patients with SMIs was 14.5 com-
pared with 10.3 for the general population [5]. Factors
affecting patients with SMIs which contribute to these
outcomes include more frequent physical comorbidities
as compared to the general population [6], genetic pre-
disposition to certain pathologies [7-9], eating habits and
sedentary lifestyles [10,11], high levels of cigarette smok-
ing and drug abuse [12-14], limited access to regular
health care services [15,16], and potential adverse events
arising during pharmacological treatment [17].
Weight gain and metabolism disturbances are among
the well documented potential adverse events related to
antipsychotic medication. A recently published meta-
analysis shows that some second-generation antipsycho-
tics (SGAs), such as olanzapine, lead to substantially
more metabolic side effects than other SGAs [18].
The majority of studies used to perform the head-to-
head comparisons with olanzapine were less than 1 year
in length. Other studies have shown no statistical differ-
ences between olanzapine and other antipsychotics
(typical and atypical) in weight gain and metabolic distur-
bances after 1 year of treatment [19-21], although signifi-
cantly greater weight gain was found in olanzapine
compared with risperidone and haloperidol after 3
months of treatment [22]. Regardless, a different pattern
of weight gain in olanzapine compared with other anti-
psychotics is proposed [21].
In recent years the importance of physical health in
patients with SMI has become increasingly recognized by
the medical community [11] and, as a result, several
guidelines and consensus recommendations [16,23-25]
have been developed in order to define the standards for
the management of physical health in this group of
patients.
Several studies have investigated the genetic vulner-
ability of psychiatric patients with regard to physical
health factors. Non-affective psychosis appears to be
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marker of cellular senescence), elevated 2-h glucose
levels, and increased pulse pressure, which are indices
that have been linked to accelerated aging and a predis-
position to diabetes mellitus and hypertension [26].
Additionally, one study has shown abnormal function of
a d u l ts t e mc e l l s( S C )i nt h ese patients, suggesting a
potential contribution to the high prevalence of medical
problems in this population. However, these results have
to be replicated and further examination of SC function
should be conducted [27].
In addition to this genetic vulnerability, there are other
risk factors that could be considered as modifiable. A
recent position statement [28] has been published by the
European Psychiatric Association (EPA), supported by the
European Association for the Study of Diabetes (EASD)
and the European Society of Cardiology (ESC), with the
aim of improving the care of patients suffering from severe
mental illnesses. Cardiovascular disease (CVD) is the most
common cause of death in patients with SMI [2,29-32],
and the statement proposes a series of interventions for
the recommended management of CVD risk factors. Sev-
eral of these risk factors are modifiable, including smoking,
diabetes mellitus, hypertension, dyslipidemia, metabolic
syndrome, and obesity [33].
Pharmacological approaches for the management of
some CVD risk factors have been established [34-38], but
the aim of this article is to review the role of lifestyle inter-
ventions that may contribute to the management of modi-
fiable CVD risk factors in patients with SMI.
Methods
The aim of this literature review was to highlight the effi-
cacy of lifestyle interventions based on diet and exercise in
the management of CVD risk factors in patients with SMI
by evaluating a selective review of relevant literature focus-
ing on the vulnerability of patients with SMI to these risk
factors and the diseases associated. A Medline database lit-
erature search was performed for articles published
between 2004 and 2010 using the term ‘lifestyle interven-
tion’ linked with MeSH terms such as ‘mental disorders’,
‘diabetes mellitus’, ‘hypertension’, ‘dyslipidemia’, ‘metabolic
syndrome’, ‘obesity’,a n d‘smoking cessation’. The refer-
ence sections of articles collected during the search were
used to direct further inquiries. Cross-referencing of ear-
lier reviews and original studies identified further informa-
tion regarding the main topics of the search.
In all, 37 reports were retrieved during this search, 22
of which were original reports and 15 were reviews.
The impact of these kinds of interventions on obesity,
diabetes mellitus, dyslipidemias, metabolic syndrome,
hypertension, and smoking was evaluated. The prevalence
and potential inter-relations of these CVD risk factors in
patients with SMI were also evaluated, along with current
evidence on how improvements in the management of the
CVD risk factors may impact SMI patients’ mortality and
quality of life. Finally, the benefits of proactively imple-
menting these lifestyle interventions will be discussed.
Physical health vulnerability of patients with SMI
Although a strong genetic relationship between diabetes
mellitus and schizophrenia has been established and speci-
fic loci have been observed that link schizophrenia and
diabetes mellitus [8], the increased prevalence of diabetes
mellitus in patients with schizophrenia [39] is fuelled by
multiple factors. These factors include hereditary and
environmental factors such as less healthy lifestyles and
poorer health care, as well as side effects of antipsychotic
medications. Nevertheless, much of the increased preva-
lence can be ascribed to traditional diabetic risk factors
such as family history, physical inactivity, and poor diet
(Figure 1) [40]. Therefore, any intervention focused on
management of those factors will likely be successful in
achieving a better control of diabetes mellitus.
Diabetes mellitus, like other CVD risk factors, approxi-
mately doubles the patient’s risk of developing CVD [14].
The relationship between second-generation antipsycho-
tics and glucose abnormalities is complicated due to the
multifactorial mechanisms that underlie the development
of diabetes mellitus [41], but it is widely accepted that the
rate of diabetes mellitus is increased in people with schizo-
phrenia in comparison with the general population [42].
Many other studies describe an increased prevalence as
compared to the general population of diabetes mellitus in
psychiatric patients [8,43], especially those with particular
psychiatric illnesses such as schizophrenia or bipolar disor-
der, and this increase seems to be independent of age,
race, gender, use of medication, or body mass [44]. People
Figure 1 Factors influencing the risk of diabetes mellitus
among patients with schizophrenia. Reprinted from Holt RI, et al.
Diabetes Obesity & Metababolism 2006, 8:125-135. Reproduced with
permission from John Wiley & Sons.
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opment of diabetes mellitus, with estimates suggesting
prevalence between 15% and 20% [9]. The prevalence of
diabetes mellitus in the bipolar disorder population may
be as much as three times greater than in the general
population [45].
Although there is not a consistent association between
SMI and hypertension in the literature, a higher preva-
lence has been observed in patients with bipolar disorder
and with anxiety disorders; this is not clear for schizophre-
nic patients [46]. In a meta-analysis comprising 12 papers
on hypertension there was a pooled risk ratio of 1.11 (0.91
to 1.35), but there remains a weak association between
SMI and hypertension [47].
Hypertension is highly important as a CVD risk factor
[14] and, like other medical conditions, has a greater pre-
valence in patients with SMI [48]. However, a recent
work shows that hypertension was the factor receiving
more therapeutic care among the studied population;
69% of patients diagnosed with hypertension upon
admission were receiving treatment [49].
Moreover, an unhealthy lifestyle related to diet habits
and excessive sedentariness is an important contributor
to CVD risk factors such as obesity, dyslipidemia, and
metabolic syndrome. Worldwid eo b e s i t yp r e v a l e n c eh a s
a very wide range, from 80% in Nauru (an island nation
in Micronesia in the South Pacific) to 9% in the Sey-
chelles. The estimated prevalence in the Spanish adult
population aged 25 to 60 years is 15.5% (13.2% in men
and 17.5% in women) [50]. It is worth noting that in a
study conducted in individuals with SMI in the commu-
nity, 29% of men and almost 60% of women with SMI
were obese [51].
The prevalence of obesity in patients with SMI is
equal or higher than that of the general population
[28,51-53], with antipsychotic medication as the contri-
buting factor [52,54,55]. This effect has been observed
to have different ranges for typical and atypical antipsy-
chotics [56]. But medication is not the sole underlying
factor for weight gain in patients with SMI, as there are
multiple factors contributing to the risk of obesity
among patients with schizophrenia including poor diet-
ary habits, and inactivity [52]. Finally, it should be noted
that body weight is regulated by a multifactorial
mechanism composed of genetic and environmental
factors, endocrinologic and metabolic control, and a
delicate balance among energy intake, storage, and
expenditure (Figure 2).
Genetic
factors
Energystorage
andexpenditure
Endocrinologic
andmetabolic
control
Environmental
factors
Bodyweight
stability
Appetite
control
Figure 2 Mechanisms of body weight regulation. Adapted with permission from Wolterskluwer [56], Baptista et al. CNS Drugs 2008, 22:477-
495.
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including diabetes mellitus, coronary artery disease,
hypertension, stroke, gallbladder disease, osteoarthritis,
and several kinds of cancers. All these factors can lead to
further increases in morbidity and mortality [14,57,58].
The higher incidence of dyslipidemia in patients with
SMI is unclear in the literature. Bresee et al. [59] found a
slightly higher dyslipidemia rate in patients with schizo-
phrenia compared with the no psychiatric population; this
finding is in accordance with the high dyslipidemia rates
(hypercholesterolemia (66%) and hypertriglyceridemia
(26%)) found in other studies [49]. A meta-analysis includ-
ing 11 papers on dyslipidemia [47] did not find an associa-
tion between SMI and total cholesterol levels, but these
studies in this meta-analysis were limited by their designs
and so their conclusions mustb ec o n s i d e r e dc a r e f u l l y .
The number of comparative studies of other lipids, such
as high-density lipoprotein (HDL) cholesterol, was inade-
quate to conduct a meta-analysis. Lower HDL cholesterol
levels in people with SMI found in two studies were not
confirmed by any other studies.
The concept of metabolic syndrome has existed for
many years and has several associated features such as
central adiposity, hyperinsulinemia, hypertension, athero-
genic dyslipidemia, decreased HDL cholesterol, elevated
fasting triglycerides, and increased levels of prothrombo-
tic proteins and inflammatory markers [60]. Metabolic
syndrome prevalence varies according to several factors
such as the diagnostic criteria [61] or country analyzed
[61-63], but it is high in all analyzed studies; notably, a
prevalence of 35% to 40% exists in the US population
[62] and in developing countries studies have shown a
wide range of prevalence, from 6.5% in India to 42.0% in
Iran [63].
Prevalence of metabolic syndrome is higher in patients
with SMI [7,60]; in the schizophrenic population the pre-
valence rate is 40% to 60% compared with 27% in the
general population [42] and 40% in patients with bipolar
disorder [64]. This increase is due partially to antipsycho-
tic medications [7,65] and is associated with higher risk
of CVD [60,65].
Other unhealthy lifestyle habits also increase the risk of
CVD. It has been shown that there is a high proportion of
smoking, alcohol abuse, and drug abuse in patients with
SMI [12,13]; 85% of patients with SMI smoke, which is
three times the rate found in the general population [14].
Smoking is considered as equivalent to metabolic syn-
drome in terms of CVD risk [28]. Approximately 60% of
patients with depression and post-traumatic-stress disor-
der are smokers, while in patients with schizophrenia the
prevalence of smoking can be as high as 65% to 90% [66].
Relative risk of smoking is elevated in patients with schizo-
phrenia and bipolar disorder (elevated twofold to threefold
in both illnesses) [28].
Smoking is a highly dangerous CVD risk factor for
patients with SMI and raises the risk of CVD by 3; the risk
of CVD is increased nearly 12-fold in individuals who have
all risk factors compared with those who have none [14].
In the US, 40% of smoking-related deaths occur among
mentally ill patients and substance abusers [67].
High-risk behaviors and unhealthy lifestyle habits are
frequently found in patients with SMI, often as a result of
social deprivation and occurring together with other fac-
tors such as more frequent physical comorbidities, genetic
predisposition, limited access to regular health services,
and potential adverse events arising from pharmacological
treatment. These factors combine to contribute to this
population’s elevated risk for CVD. Choice of medication
would seem to be as a modifiable risk factor. Any potential
adverse effects of medication, particularly those that can
contribute to increase the associated risk for physical ill-
ness should be balanced against their benefits in treating
the mental illness, such as symptom control, improved
quality of life, or reducing relapse, rehospitalizations or
suicide rates.
Our review has focused in the modifiable factors asso-
ciated to physical health and how lifestyle intervention
strategies can modify the impact of such factors, espe-
cially those based on diet and exercise.
Interventions and patients with SMI
Many examples in the literature examine how lifestyle
interventions work in several aspects related to physical
health [68,69]. Lifestyle interventions that facilitate the
management of modifiable CVD risk factors are well
established and, in most cases, have common characteris-
tics, such as diet and exercise interventions [70,71]. This is
a logical consequence of considering CVD risk factors as
closely inter-related. Changes in a patient’s lifestyle based
on the successful incorporation of healthy eating and fit-
ness habits can also reduce CVD risk factors (Table 1)
[72]. We will see several examples of the efficacy of life-
style intervention in every modifiable CVD risk factor
separately and/or in combination.
Diabetes mellitus
Currently, many pharmacological approaches are avail-
able for reducing or delaying diabetes mellitus [35], but a
key piece for the initial management of the disease for
the majority of the affected population consists of life-
style modification based on changes in dietary habits and
physical activity [73].
Several studies have proven the efficacy of these lifestyle
interventions in the management of diabetes mellitus in
non-SMI patients as well [28,74]. In the early Malmö
study [75], a lifestyle intervention based on diet and exer-
cise facilitated normalized glucose tolerance in more than
50% of subjects with impaired glucose tolerance, and more
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sion after a mean follow-up of 6 years. In addition,
improvement in glucose tolerance was correlated to
weight reduction and increased fitness. The Diabetes Pre-
vention Study (DPS) [76] showed that lifestyle intervention
may prevent diabetes mellitus and reduce the risk of dia-
betes mellitus. This study showed that the reduction in
the incidence of diabetes mellitus was directly associated
with changes in lifestyle as well.
The efficacy of lifestyle interventions in patients with
SMI has been demonstrated clearly. One study investi-
gated a population of patients with schizophrenia to
evaluate the efficacy of lifestyle interventions (based on
psychoeducational, dietary, and exercise programs) and
metformin, both alone and in combination, for antipsy-
chotic-induced abnormalities in insulin sensitivity [77].
It showed that lifestyle intervention and metformin,
both alone and in combination, can improve insulin
sensitivity induced by antipsychotic medications. In
addition, lifestyle intervention plus metformin was
superior to lifestyle intervention plus placebo in decreas-
ing insulin and Insulin Resistance Index (IRI), while
metformin alone has the same effect on insulin sensitiv-
ity as lifestyle intervention plus metformin. Metformin
was superior to lifestyle intervention plus placebo in
decreasing fasting glucose, insulin levels, and IRI levels.
All three intervention groups were found to have a sig-
nificant advantage over placebo in improving weight
gain and insulin sensitivity in patients with schizophre-
nia. The addition of a lifestyle intervention seems to be
more efficacious than pharmacological treatment alone
in the management of diabetes mellitus variables.
Due to the limited effect of pharmaceutical treatment
for diabetes mellitus on glycemic control, lifestyle inter-
ventions designed to prevent an increase in blood glucose
must be initiated as soon as possible. Ideally, such inter-
ventions should begin before the clinical symptoms of
diabetes mellitus appear and before glucose levels are
high enough to be classified in the range for diabetes
mellitus. The risk of complications has already begun in
the prediabetic phase before the patient’s blood glucose
levels reach diagnostic cut-off points for diabetes melli-
tus. In light of this, waiting until individuals attain the
diagnostic criteria for diabetes mellitus will result in sig-
nificant morbidity and mortality from cardiovascular dis-
ease [78].
Hypertension
Lifestyle interventions have proven efficacy in the man-
agement of hypertension. The PREMIER trial [79] tested
the effects of two multicomponent lifestyle interventions
on patients with hypertension relative to a control group
and observed reductions of 12% to 14% in estimated
CVD risk (estimated from the Framingham risk equa-
tions). A review of lifestyle interventions with intentional
weight loss showed that those lifestyle interventions were
effective in reducing systolic blood pressure, although the
evidence for diastolic blood pressure was less convincing
[80]. A reduction in hypertension values was observed in
patients with SMI who followed a lifestyle intervention
based on diet and exercise, but that decrease was not sta-
tistically significant [81]. Lifestyle changes such as stop-
ping smoking, reducing salt intake, reducing body
weight, and increasing exercise may be sufficient to
reduce mildly elevated blood pressure [28].
Obesity
Programs of lifestyle intervention designed to establish
good nutritional and exercise habits have showed efficacy
in reducing weight gain and in the treatment of obesity.
A systematic review performed to evaluate the effective-
ness of long-term lifestyle interventions in preventing
weight gain found a wide range of results in the different
studies reviewed, but it was apparent that diet, alone and
with the addition of exercise and/or behavioral therapy,
led to significant weight loss and improvement in meta-
bolic syndrome and diabetes mellitus for at least 2 years,
compared with a control group that received no treat-
ment [70].
These kinds of lifestyle interventions have proven effi-
cacy in reducing weight gain in patients with SMI with
very promising results [51,82,83], and preventive
approaches have the potential to be more effective, accep-
table, cost efficient, and beneficial [54]. A structured pro-
g r a ms p o n s o r e db yE l iL i l l ya n dC o .( g e n e r a l l yc a l l e d
Solutions for Wellness) is based primarily on exercise and
Table 1 Therapeutic lifestyle changes for patients at high cardiovascular and metabolic risk: risk factors and goals/
recommendations
Abdominal obesity Physical inactivity Atherogenic diet
7% to 10% loss of body weight from baseline 30 to 60 min of moderately intense aerobic activity daily Saturated fat <7% of total calories
Caloric deficit of 500 to 1,000 kcal* daily Reduce intake of trans fat
Physical activity Dietary cholesterol <200 mg/dl*
Total fat 25% to 35% of total calories
*To convert values to SI units: 1 kcal = 4.2 kJ; for cholesterol, 1 mg/dl = 0.02586 mmol/l.
Adapted with permission from American Journal of Medicine [72], Grundy SM. Am J Med 2007, 120(Suppl 1):S3-S8.
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tries. When carried out in a US population, this program
demonstrated that people with mental illness have the
desire to improve their health and well-being [84]. Patients
achieved a mean body mass index (BMI) reduction of 0.93
kg/m
2 at the end of the 6-month observation period
[85,86], with results similar to those of another study
which showed differences in weight gain between the
intervention group and the standard care group, the latter
of which had gained a significant amount of weight by the
end of the study [86].
A 4-week study carried outi na nI r i s hp o p u l a t i o n
showed that by discontinuation of engagement with the
program, only 14/47 (30%) patients had gained weight
during a mean follow-up of 24 days (median 14 days) and
the remainder either maintained their weight or lost
weight [87]. Similar results in BMI reductions have been
observed in a Korean population in a study of 12 weeks’
duration [88,89]. These programs have also demonstrated
efficacy in the population of patients with SMI in long-
term weight management (2, 4, and even 8 years) [90,91].
Although these studies have shown the efficacy of Solu-
tions for Wellness programs in the management of para-
meters such as weight gain, BMI, and abdominal
circumference, the results are not really conclusive due
to limitations in the studies design, such as the absence
of a control group. It would be advisable to perform addi-
tional studies with more control and detailed designs to
evaluate deeper the efficacy of this program.
Dyslipidemia and metabolic syndrome
Effective management of dyslipidemia and metabolic syn-
drome may be implemented by working on the reduction
of obesity and weight gain. A good example of a lifestyle
intervention program with the objective of managing
weight gain that has been induced by antipsychotics in
patients with SMI is the study by Poulin et al. performed
in a Canadian population [92]. It was a prospective, com-
parative, and open-label study carried out on a total of 110
patients with schizophrenia and schizoaffective or bipolar
disorders being treated with atypical antipsychotics. Of
these patients, 59 (experimental group) participated in an
18-month weight-control program that included dietary
education and physical activity counseling as well as a
structured, supervised, facility-based exercise program in a
small gymnasium, consisting of 90 min of physical activity
counseling provided at the beginning of the study and
delivered by a nutritionist and a psychiatric nurse.
A kinesiologist supervised small groups who were
devoted to exercise sessions performed for 60 min twice
a week. The control group consisted of 51 patients who
did not participate in the clinical program. Anthropo-
metric and metabolic parameters were analyzed.
At the study endpoint, investigators observed reduc-
tions in the active group for the anthropometric vari-
ables that differed substantially from the control group:
body weight (difference of 6.7 kg, P <0.01), BMI (differ-
ence of 3.2 kg/m
2, P <0.01), and waist circumference
(difference of 9.3 cm, P <0.01). Regarding metabolic
parameters, at the study endpoint significant mean dif-
ferences between the two groups were observed in total
cholesterol, low-density lipoprotein (LDL) cholesterol,
HDL cholesterol, triglycerides, and fasting glucose con-
centrations. Glycosylated hemoglobin (HbA1C) signifi-
cantly decreased (-11.4%) compared to baseline in the
active group. This study demonstrates that not only
body weight but metabolic risk profile can be effectively
managed with a weight-control program that includes
physical activity.
Furthermore, it has been shown that relatively small
weight loss can confer health benefits. A loss of just 5% of
body weight in obese individuals may result in clinically
meaningful reductions in morbidity and mortality, as well
as additional improvements in glucose control in those
with diabetes mellitus. Similarly, weight reduction in an
overweight (BMI >25) individual may lead to reduction in
blood pressure [93]. Even moderate weight loss (10% or
less) has been associated with improved insulin action,
decreased fasting blood glucose, and decreased need for
diabetes mellitus-related medications [94].
An analysis of the efficacy of lifestyle intervention pro-
grams in the reduction of blood lipids in patients with
SMI [94,95] versus a population with no mental illness
[76,96] reveals a moderate effect that is only significant in
the case of triglycerides; its efficacy with regard to LDL
and HDL is less clear and the statistical significance varies
among studies. Lifestyle interventions have demonstrated
efficacy in reducing rates of metabolic syndrome [65,95],
in which the key component for change is the reduction of
body fat percentage. Weight loss is the major determinant
in maximizing effectiveness in improving metabolic syn-
drome parameters [74]. Small changes in body fat can eli-
cit changes in metabolic syndrome, which may ultimately
translate into changes in risk of CVD [95].
Smoking cessation
The effectiveness of lifestyle intervention in smoking
cessation has been studied when the intervention con-
sists only of lifestyle counseling and its combination
with pharmacotherapy. The effectiveness of lifestyle
interventions (including pharmacological treatment) in
smoking cessation has been proven in patients with SMI
[97-100]. However, there are data that suggest that
patients with a history of mental health disorders are
less likely to quit smoking and have lower cessation
rates than the general population [66]. Lifestyle
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more effective when a pharmacological treatment (nico-
tine replacement therapy or bupropion) is adjuvant
[98,99]. Rigotti et al. [101] performed a systematic
review to study the effectiveness of smoking cessation
interventions. The effectiveness of lifestyle interventions
in smoking cessation consisting of counseling is estab-
lished, and the addition of a pharmacological treatment
increases the rate of quitting.
Conclusions
The physical health of patients with SMI should be part
of the field of action of psychiatric practitioners, and
global health (physical and mental) is a universal goal at
present time. The objective of reducing the risk of CVD
in patients with SMI is crucial given the particular vul-
nerability of this population to physical illnesses and the
fact that CVD is the most common cause of death in
patients with SMI.
Strong evidence confirms the efficacy of lifestyle inter-
ventions based on diet and exercise in the management
of CVD risk factors. The clear inter-relation and inter-
dependence among all CVD risk factors means that
improving one of them through lifestyle intervention
programs can lead to a concomitant improvement in
the other factors as well (Figure 3). This is particularly
evident in the case of obesity or weight gain, where all
lifestyle interventions based on diet and exercise that
leads to weight reduction achieve benefits in other phy-
sical health parameters, such as metabolic ones.
It may seem obvious to conclude that a healthy life-
style with healthy nutrition and regular physical activity
is efficacious in achieving good physical health, even in
patients with SMI. But we can only wonder about the
number of patients with SMI presenting an increase in
one of the CVD risk factors invited to participate in a
lifestyle intervention program, notwithstanding the
strong scientific evidence supporting their efficacy for
the improvement of those factors. Moreover, if we take
into account that several studies suggest that a genetic
vulnerability exists in these patients independent of the
antipsychotic treatment [8,26], the preventive implemen-
tation of lifestyle intervention programs should be con-
sidered good practice in treating these patients.
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